Intensive Case Management for Substance Use Disorders (RCT) (ICM)
Intensive Case Management for Patients With Substance Use Disorders and Complex Psychosocial Needs: A Randomized Controlled Trial
This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.
Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).
Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.
In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:
- People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
- people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
- patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
- people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.
Sex and gender will be treated as potential covariates and will be considered in the analysis.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Johannes Senesi, MSc
- 電話番号:+41564622670
- メール:johannes.senesi@pdag.ch
研究場所
-
-
Canton of Aargau
-
Windisch、Canton of Aargau、スイス、5210
- 募集
- PDAG
-
コンタクト:
- Johannes Senesi, MSc
- 電話番号:+41564622670
- メール:johannes.senesi@pdag.ch
-
主任研究者:
- Johannes Senesi, Msc
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 4 or more inpatient admissions in the last 24 months
- Diangosed SUD
- Residence or temporary stay in the canton of Aargau
Exclusion Criteria:
- any emergency situation requiring psychiatric or hospital admissions
- inability to give informed consent
- acute, unstable psychotic symptoms
- acute risk of harm to self or others
- insufficient german language skills
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Experimental
receives ICM immediately |
Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement:
|
|
アクティブコンパレータ:Waiting List
Same as Experimental, only with 6-Month TAU-Waiting List before ICM |
TAU will take place for 6 months before starting with ICM |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Inpatient Admissions (Health Service utilisation)
時間枠:6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Number of Inpatient Days (Health Service utilisation)
時間枠:6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
WHOQoL-BREF
時間枠:6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Quality of Life |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
SFQ
時間枠:6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Social Functioning Questionnaire |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ASSIST
時間枠:6 Months (exploratory), 24 months (exploratory)
|
Substance use characteristics |
6 Months (exploratory), 24 months (exploratory)
|
|
Continuity of Care (Brice-Boxerman)
時間枠:6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Continuity of Care describes timeframes of the health services used outside the ward. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Linking
時間枠:6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management. |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
Retention
時間枠:6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
Retention describes the voluntary staying of patients in the ICM treatment |
6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
|
|
BSCL
時間枠:6 Months (exploratory), 24 months (exploratory)
|
Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care |
6 Months (exploratory), 24 months (exploratory)
|
|
EQ-5D-5L
時間枠:6 Months (exploratory), 24 months (exploratory)
|
EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER) |
6 Months (exploratory), 24 months (exploratory)
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- PDAG-ICM
- HumRes68440 (その他の識別子:Human Research Switzerland (HumRes))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。